blown leukemia chronic myeloid leukemia and their contribution to inducing murine Functional features of RUNX 1 mutants in acute transformation

http://bloodjournal.hematologylibrary.org/content/119/12/2873.full.html Updated information and services can be found at: (702 articles) Myeloid Neoplasia • Articles on similar topics can be found in the following Blood collections http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml Information about subscriptions and ASH membership may be found online at:

[1]  A. Kohlmann,et al.  A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases , 2011, Leukemia.

[2]  Chuanfeng Wu,et al.  C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice , 2011, Proceedings of the National Academy of Sciences.

[3]  G. Stein,et al.  The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes , 2010, Journal of cellular physiology.

[4]  Chieh-Yu Liu,et al.  AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.

[5]  H. Harada,et al.  AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. , 2009, Blood.

[6]  Hiroaki Honda,et al.  Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia. , 2009, Blood.

[7]  C. So,et al.  Transforming activity of AML1-ETO is independent of CBFβ and ETO interaction but requires formation of homo-oligomeric complexes , 2009, Proceedings of the National Academy of Sciences.

[8]  R. Ono,et al.  AML1 mutations induced MDS and MDS/AML in a mouse BMT model. , 2008, Blood.

[9]  Saijuan Chen,et al.  Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia , 2008, Proceedings of the National Academy of Sciences.

[10]  C. Preudhomme,et al.  RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. , 2007, Blood.

[11]  G. Nucifora,et al.  RUNX1-RUNX1 Homodimerization Modulates RUNX1 Activity and Function* , 2007, Journal of Biological Chemistry.

[12]  S. Tsuzuki,et al.  Isoform-specific Potentiation of Stem and Progenitor Cell Engraftment by Aml1/runx1 Methods and Findings , 2022 .

[13]  G. Stein,et al.  Subnuclear targeting of Runx1 Is required for synergistic activation of the myeloid specific M‐CSF receptor promoter by PU.1 , 2005, Journal of cellular biochemistry.

[14]  F. Mikhail,et al.  The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro. , 2005, Cancer research.

[15]  S. K. Zaidi,et al.  Point mutation in AML1 disrupts subnuclear targeting, prevents myeloid differentiation, and effects a transformation-like phenotype. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[17]  J. Kutok,et al.  Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. , 2004, Blood.

[18]  B. Calabretta,et al.  The biology of CML blast crisis. , 2004, Blood.

[19]  M. Greaves,et al.  Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Motomi Osato.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia , 2004, Oncogene.

[21]  G. Nucifora,et al.  SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo , 2003, Oncogene.

[22]  T. Inaba,et al.  Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. , 2003, Blood.

[23]  G. Sauvageau,et al.  Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. , 2002, Blood.

[24]  Yoshiaki Ito,et al.  In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. , 2002, Blood.

[25]  R. Ren,et al.  Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia , 2001, Oncogene.

[26]  Takashi Kumasaka,et al.  Structural Analyses of DNA Recognition by the AML1/Runx-1 Runt Domain and Its Allosteric Control by CBFβ , 2001, Cell.

[27]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[28]  M. Kurokawa,et al.  Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. , 2000, Blood.

[29]  S. Minucci,et al.  Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. , 2000, Molecular cell.

[30]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[31]  J. Darnell,et al.  The Significance of Tetramerization in Promoter Recruitment by Stat5 , 1999, Molecular and Cellular Biology.

[32]  A. Courey,et al.  A Role for Groucho Tetramerization in Transcriptional Repression , 1998, Molecular and Cellular Biology.

[33]  J. Lu,et al.  Identification of an upstream enhancer containing an AML1 site in the human myeloperoxidase (MPO) gene. , 1998, Leukemia research.

[34]  A. Schedl,et al.  The Wilms' tumor suppressor WT1: approaches to gene function. , 1998, Kidney international.

[35]  M. Meisterernst,et al.  A conserved tissue-specific structure at a human T-cell receptor beta-chain core promoter , 1997, Molecular and cellular biology.

[36]  J. Zhang,et al.  AML1A and AML1B can transactivate the human IL-3 promoter. , 1997, Journal of immunology.

[37]  R. Bronson,et al.  Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Downing,et al.  AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis , 1996, Cell.

[39]  J. Rowley,et al.  AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. , 1995, Blood.

[40]  N. Pavletich,et al.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms , 1995, Science.

[41]  Y. Ito,et al.  Subcellular localization of the alpha and beta subunits of the acute myeloid leukemia-linked transcription factor PEBP2/CBF , 1995, Molecular and cellular biology.

[42]  A. Look,et al.  Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1) , 1994, Molecular and cellular biology.

[43]  C. Jamieson.  Chronic myeloid leukemia stem cells. , 2008, Hematology. American Society of Hematology. Education Program.

[44]  Letizia Foroni,et al.  Core binding factor genes and human leukemia. , 2002, Haematologica.

[45]  O. Bernard,et al.  A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL–PDGFRβ oncoprotein , 1997, The EMBO journal.